Clinuvel Pharmaceuticals Ltd
CUVLDrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Afamelanotide
Erythropoietic Protoporphyria
Afamelanotide and NB-UVB Light
Vitiligo
Afamelanotide implant
Erythropoietic Protoporphyria
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Afamelanotide | Phase 3 | Erythropoietic Protoporphyria | - | - |
Afamelanotide and NB-UVB Light | Phase 3 | Vitiligo | - | - |
Afamelanotide implant | Phase 2 | Erythropoietic Protoporphyria | - | - |
Frequently asked questions
What is in Clinuvel Pharmaceuticals Ltd's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Clinuvel Pharmaceuticals Ltd's (CUVL) pipeline across Phase 3, Phase 2. Its lead program is Afamelanotide (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Clinuvel Pharmaceuticals Ltd's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Clinuvel Pharmaceuticals Ltd (CUVL) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CUVL biotech catalysts?→
Add CUVL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Clinuvel Pharmaceuticals Ltd's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.